Aiming To Lead A Global Operation? Start In China!
Executive Summary
Moving from China president to a CEO, from regional Asia head to a global pharmaceutical president, several recent senior executive appointments have people wondering if China is increasingly becoming the new launch pad for high flyers eyeing a global pharma leadership role.
You may also be interested in...
Asia Executives To Watch: Novartis China, GSK India, Cipla
Novartis’s former head of West China is moving to lead its global cardio-metabolic franchise, while GSK India and Cipla have made key personnel appointments on the manufacturing front.
Ascletis Eyes Launch Of China’s First Oral HCV Drug, Possible IPO
Already well-funded Chinese venture Ascletis has completed a large Series B to support the commercialization of effective new oral HCV drugs and progress its pipeline, and has not ruled out the possibility of going public in an IPO.
China Set To Green-Light First mRNA Vaccine
In what appears to be a step towards a gradual shift away from its strict "COVID Zero" policies, China is poised to approve its first mRNA vaccine - in this case developed domestically - and will accelerate the roll-out of COVID-19 vaccinations in general to seniors over 80.